Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.